期刊名称：JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY ISSN： 2156-5333 出版频率： Bi-monthly 出版社： MARY ANN LIEBERT, INC, 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, USA, NY, 10801   出版社网址： http://www.liebertpub.com/Default.aspx 期刊网址： http://www.liebertpub.com/overview/journal-of-adolescent-and-young-adult-oncology/387/ 影响因子： 2.223 主题范畴： ONCOLOGY 变更情况： 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal ISSN: 2156-5333 • Online ISSN: 2156-535X OVERVIEW Journal of Adolescent and Young Adult Oncology (JAYAO) breaks new ground as the first cancer journal dedicated to all aspects of adolescent and young adult (AYA)-aged cancer patients and survivors. JAYAO is the only central forum for peer-reviewed articles, reviews, and research in the field, bringing together all AYA oncology stakeholders and professionals across disciplines, including clinicians, researchers, psychosocial and supportive care providers, and pediatric and adult cancer institutions. JAYAO covers multidisciplinary issues specific to AYAO patients and survivors such as: Diagnosis Clinical trials Therapeutic approaches Oncofertility Psychosocial issues Survivorship Quality of life Journal of Adolescent and Young Adult Oncology is under the editorial leadership of Editor-in-Chief Leonard S. Sender, MD, University of California, Irvine and CHOC Children’s Hospital, and other leading clinicians and researchers. View the entire editorial board. Audience: Pediatric and adult hematologists and oncologists, surgical oncologists; radiation oncologists; pediatricians and adolescent medicine specialists; reproductive endocrinologists; oncology nurses and advanced practice staff; social workers; cancer researchers, among others Society Affiliation The Official Journal of: Society for Adolescent and Young Adult Oncology Learn more about SAYAO and become a member today.                               View SAYAO's YouTube Channel 2014 SAYAO Conference...Video Highlights 2013 SAYAO Conference...Video Highlights Teenage Cancer Trust   Indexed/Abstracted in: MEDLINE; PubMed; PubMed Central; Science Citation Index Expanded; Journal Citation Reports/Science Edition; EMBASE/Excerpta Medica; CINAHL® database; PsycINFO Instructions to Authors Manuscript Submission Guidelines Journal of Adolescent and Young Adult Oncology (JAYAO) welcomes quantitative and qualitative clinical, basic science, and psychosocial manuscript submissions on all topics related to adolescent and young adult-aged cancer patients and survivors, including AYA-aged survivors of pediatric cancer. JAYAO generally uses the National Cancer Institute's designated AYA age range of 15-39; however, it is acceptable for manuscripts submitted from institutions or countries typically using a younger lower age limit to use the lower age limit as appropriate. For a discussion about the age range included in adolescent and young adult oncology, please see the Controversies piece in JAYAO's inaugural issue (J Adolesc Young Adult Oncol. 2011;1(1):3-10).   SPECIAL OPEN ACCESS publishing option -- Contact:  OpenAccess@liebertpub.com   Article Types Note: All articles are peer-reviewed unless otherwise noted. Note the listed limits for text, figures/tables, and references below, but please be concise across all manuscript components. Those interested in an exception to a posted limit must contact the Editors prior to submission. Original Articles present original quantitative or qualitative basic science, clinical, or psychosocial research Abstract: Standard abstract 250 word limit. See standard abstract guidelines under Manuscript Components. Text: 3,000 word limit. Figures and Tables: Maximum of 8 total figures and/or tables. References: Maximum of 100 references. Review articles are systematic and critical reviews of the current literature on a topic Abstract: Standard abstract 250 word limit, but structured headings not required. Text: 4,500 word limit. Details on the study selection and inclusion process and on the participants in each selected study should be included. Figures and Tables: Maximum of 10 total figures and/or tables. References: Maximum of 250 references. Case Study articles are unusual, illustrative, or instructive AYAO-relevant clinical cases Abstract: Include a brief abstract of 100 words or less; structured headings are not required. Text: 1,750 word limit. Include a concise literature review, brief overview of the case, and a brief summarizing conclusion. Be sure to discuss the relevance or importance of the case to AYAO. Figures and Tables: Maximum of 3 total figures and/or tables. References: Maximum of 25 references. Brief Reports articles are short pieces about pilot studies, preliminary findings, very small sample sizes, or other research findings that are not suitable for a full Original Article Abstract: Include a brief abstract of 100 words or less; structured headings are not required. Text: 2,000 word limit. Include a concise literature review and a brief overview of the study, sufficient details on the study's methods and analysis, and a brief summarizing conclusion. Figures and Tables: Maximum of 3 total figures and/or tables. References: Maximum of 25 references. Perspective articles are short pieces in which authors share or argue a viewpoint grounded in the literature but not linked to a specific article Abstract: The final print version of accepted Perspective articles will not have an abstract. However, please include a maximum 100 word abstract with the submission to facilitate the review process. Text: 1,500 word limit. The first paragraph should be a brief overview as there is no abstract. The perspective and points should be grounded in the literature. Include a brief summarizing conclusion. Figures and Tables: Maximum of 3 total figures and/or tables. References: Maximum of 25 references. Letters to the Editor comment on recently published JAYAO articles Special Notes: Letters to the Editor should be submitted within 6 weeks of the article's publication in print form. Include a short title related to but distinct from the recently published article. Provide the standard Title page, but no Running Head or Keywords. The Editors may choose to invite the authors to submit a response to the Letter. Not peer reviewed. Abstract: The final print version of accepted Letters to the Editor will not have an abstract. However, please include a maximum 100 word abstract with the submission to facilitate processing. Text: 500 word limit. Figures and Tables: Maximum of 1 total figure and/or table. References: No more than 5 references, one of which must be the JAYAO article being discussed. Article Types that are Invite-Only or Require Pre-Submission Inquiry Roundtable articles are transcribed discussions on a topic by leading members of the AYAO community Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed. Controversies articles include short responses by invited participants to hot topics in AYAO Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed. Clinical Trial Spotlight articles are brief summaries of clinical trials of importance or relevance to AYAO and still open to accrual Invitation only, although those with a suggested topic are welcome to contact the Editors. Not peer reviewed. Editorial pieces provide commentary and analysis of an article in the issue of JAYAO in which it appears Invitation only. Not peer reviewed. Book Reviews are 500-750 word pieces critically reviewing a book of AYAO-relevance Invitation only, although those with a suggestion of a book to be reviewed are welcome to contact the Editors. Not peer reviewed. Special Articles may include guidelines, meeting summaries, consensus statements, or other non-standard communications Please contact the Editors prior to submission. May be subject to peer review. Online Manuscript Submission Manuscripts must be uploaded to Manuscript Central in a word processing format, preferably in Microsoft Word. Do not submit the manuscript or any of its components in PDF format. All authors on a submitted manuscript must have a Manuscript Central account. Keywords and Abstract Please note the keywords and abstract entered online in Manuscript Central are only to aid with the review process and are separate from the keywords and abstract on the title page for inclusion in the article. Suggested Reviewers Authors are encouraged to suggest the names and emails of appropriate reviewers, at least one of whom is not a member of JAYAO’s Editorial Board, during Manuscript Central submission, though final selection of reviewers is at the discretion of the Editors. Cover Letter Please include a cover letter from the corresponding author. The cover letter should include the following: Running head character count (including spaces) Abstract word count Main text word count Number of tables Number of figures Number of appendices (if applicable) If the authors have published or submitted any related papers from the same study If pre-submission permission was obtained to exceed the article type’s word limit Authors are encouraged to detail the significance and uniqueness of the work PUBLICATION ETHICS AND MALPRACTICE STATEMENT   Study Design and Ethics Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript. Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements. Definitions of Scientific Misconduct Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI). Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following: Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.  Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist. Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct. Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud. Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct. Conflict of Interest:  Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct. Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud. Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud. Simultaneous Submission:  Submitting a paper to more than one publication at the same time constitutes misconduct. Responding to Allegations of Possible Misconduct The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation.  As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred. When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper.  In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated. Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution. If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record.  If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal. All allegations will be kept confidential. Manuscript Components General Formatting and Style Use of English Language: All submissions must be in English. JAYAO uses American-style English Plagiarism: All submitted manuscripts will be processed through plagiarism detection software. Plagiarized manuscripts will be rejected Word limits: See word limits under Article Types. Word limits do not include the Title Page, headings, Abstract, Acknowledgments, Disclaimer, Author Disclosure Statement, References, Figures, Tables, or legends. Permission to exceed an article type’s word limit must be given by the Editors prior to submission Font: Times New Roman or Arial in 12-point type Abbreviations: Expand all abbreviations at first mention in the text Page size: Letter size (8.5 x 11 inches) Margins: 1 inch Line and word spacing: Double-space all lines; single-space all words Page numbering: Number all pages in the lower-right corner. Do not include anything else in the header or footer Title Page The title (first) page of all manuscripts must contain the following information: Exact title: No proprietary names, trade names, or abbreviations For each author: Full name, including middle initial if applicable Primary academic degrees (such as MD, DO, PhD, MPH, etc. No undergraduate or honorary degrees, fellowship or society memberships, etc.) Institutional affiliation(s) City, state, and country for each affiliation Email address Note: - Group authors (i.e., “…on behalf of the XYZ Study”) are permissible - Co-first authors are also permitted. On the title page, please put an asterisk after each co-first author and note them as such Corresponding author: Full name, including middle initial if applicable Primary academic degrees (such as MD, DO, PhD, MPH, etc. No undergraduate or honorary degrees, fellowship or society memberships, etc.) Institutional affiliation(s) City, state, and country for each affiliation Full mailing address Phone number Fax number Email address Running head: 60 characters or fewer (including spaces, abbreviations acceptable) Keywords: Provide 4-6 keywords to be included in the article Please do not use cancer, oncology, AYA, or adolescent and young adult as these are inherent in the journal itself Abstract A structured abstract using the following guidelines should accompany every manuscript unless otherwise noted above under Article Types. The abstract should appear on a separate page after the title page. The abstract should be no more than 250 words, formatted with the following headings:               - Purpose               - Methods               - Results               - Conclusion Do not use proprietary or trade names References are not permitted in the abstract Headings do not contribute toward abstract word count Acknowledgments After the Conclusion of the main body of the manuscript, include a separate section acknowledging any contributors who did not meet the requirements for authorship and any science writers or corporate employees who participated in the development of the manuscript. Also include acknowledgments of research support for the study. Disclaimer After the Acknowledgments section, include a “Disclaimer” section, if needed, for the following: Detail any important disclaimers (for example, the primary data collection organization for a secondary-analysis article) Provide all appropriate details if any part of the manuscript was previously presented Author Disclosure Statement Following the Acknowledgments section (or Disclaimer if one was included), include a section entitled ‘‘Author Disclosure Statement.’’ Here authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals for further guidance. If no conflicts exist, the authors must state ‘‘No competing financial interests exist.’’ References Authors are responsible for the accuracy and completeness of their references. Number references in the order they are cited in the text; do not alphabetize. In-text citations should be in numerical order, superscripted, not contained within parentheses or brackets, and placed after punctuation. Reference section: Check the Article Types section for reference number limits for some article types Begin the Reference section on a separate page after the Author Disclosure Statement section Double-space all lines and single-space between words Articles accepted and in press are included in the Reference section Personal communications, unpublished data, or manuscripts “in preparation” or “submitted for publication” should not be included in the Reference section. If necessary, these should be included at the appropriate place in the body of the text. Personal communications should include the contact’s first initial and last name, and the month and year of the communication List all authors and/or editors up to 4; for 5 or more, list the first 3 followed by “et al.” For books, volume and edition numbers should be included when appropriate Abbreviate journal names in accordance with PubMed / MEDLINE    No PMIDs or PCMIDs References that are abstracts should be indicated as such, with the abstract number included, if applicable Citation formats are based on NLM style, please see below for specific JAYAO format examples Examples: Journal article with 1-4 authors: 1.   Evan EE, Kaufman M, Cook AB, Zeltzer LK. Sexual health and self-esteem in adolescents and young adults with cancer. Cancer. 2006;107(7 Suppl):1672-9. Journal article with 5 or more authors: 2.   Absolom K, Eiser C, Michel G, et al. Follow-up care for cancer survivors: views of the younger adult. Br J Cancer. 2009;101(4):561-7. Abstract: 3.   Mullighan CG, Miller CB, Phillips LA, et al. IKZF1 (Ikaros) deletions are a hallmark of BCR-ABL1 positive acute lymphoblastic leukemia. Blood. 2007;110:abstract 721. Book: 4.   Quinn GP, Vadaparampil ST (Eds). Reproductive health and cancer in adolescents and young adults. New York: Springer; 2012. Chapter in a Book: 5.   Eiser C, Kuperberg A. Psychological support for adolescents and young adults. In: Bleyer WA, Barr RD (Eds). Cancer in adolescents and young adults. New York: Springer; 2007; pp. 365-74. Report: 6.   Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: research and cancer care imperatives for adolescents and young adults with cancer (NIH Publication No. 06-6067). Bethesda, MD: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, and the LIVESTRONG Young Adult Alliance; August 2006. Accessed February 7, 2011 from: http://planning.cancer.gov/library/AYAO_PRG_Report_2006_FINAL.pdf Tables Within the text, cite tables in the order in which they appear using Arabic numerals. Tables in accepted articles will be typeset and placed near the first mention of the table in the text; do not include separate lines indicating table placement. Table guidelines: Check the Article Types section for limits on the number of tables and/or figures for some article types Either prepare all tables on separate pages in the main document following the References section OR submit each table as a separate word processing document. Do not embed tables within the main body text Provide a brief but descriptive title for each table. Avoid abbreviations in the table title when possible Table footnote(s) should include any essential notes and must include definitions of all abbreviations and acronyms used in the table Figures Within the text, cite figures in the order in which they appear using Arabic numerals. Figures in accepted articles will be typeset and placed near the first mention of the figure in the text; do not include separate lines indicating figure placement. Figure guidelines: Check the Article Types section for limits on the number of tables and/or figures for some article types Figures include graphs, charts, diagrams, illustrations, and photographic images File types and guidelines: - All figures must be submitted as separate picture files. Do not embed figures in the main word processing document - Do not submit figures as PDFs, PowerPoint, or Excel files - To ensure proper print quality, please submit only TIFF or EPS files. JPEG files are for screen representation-quality only and will print very poorly during the printing process - Line illustrations should be submitted at 900 DPI.  Halftones and color should be submitted at a minimum of 300 DPI Color figures: - Color art must be saved as CYMK, not RGB. (Note: If RGB files are submitted, the files will be converted to CYMK and some color variation will occur) Figure legends: - After the Reference section of the main word processing document (or any Tables included in the word processing document), include a separate page with the following information for each figure: - Provide a brief but descriptive title for each figure. Avoid abbreviations in the figure title when possible - Define all relevant information in figures, including figure part labels, footnotes, abbreviations, acronyms, arrows, and levels of magnification in insets   Online-Only Materials Appendices and other supplementary materials should be included only when they are pertinent to the submitted manuscript but beyond the word or table/figure limits. Appendix and supplementary material guidelines: Published only with the online version of an accepted article The print version of the article will include a URL directing readers to the online-only materials Should be important to understanding or interpretation of the manuscript and limited in length Should be original and not previously published Acceptance of online-only materials is separate from acceptance of the manuscript and at the Editors’ discretion Authors are encouraged to contact the Editors prior to submission of online-only materials Helpful Hints Clarification of ‘AYA’: Abstracts and the beginning of manuscripts should clearly distinguish whether ‘AYA-aged patients,’ ‘AYA-aged survivors (of AYA cancer),’or ‘AYA-aged survivors (of pediatric cancer)’ are being discussed Variations of ‘AYA’: Authors should use the terminology most appropriate to their manuscript’s age range and country or institution. While ‘adolescent and young adult (AYA)’ is most commonly used in JAYAO, ‘teenage and young adult (TYA),’ ‘young adult (YA),’ adolescent, and other such variations may be used as appropriate Description of age: All manuscripts must clearly state the age range included in both the abstract and main body. Manuscripts discussing survivors must include information about participants’ age both at diagnosis and at study Background and introduction of AYAO in manuscripts: As JAYAO is an entirely AYA-focused journal, please be mindful that the background or introduction section of a manuscript submitted to JAYAO may not need to be as long nor as detailed as an AYAO-focused manuscript submitted to another journal Pre-submission inquiry for manuscripts exceeding word limits: Permission to exceed an article type’s word limit must be given by the Editors prior to submission Revision word limits: Article type word limits apply to revisions as well as initial submissions Pre-submission inquiry for manuscripts with online-only appendices: Authors are encouraged to contact the Editors prior to submission of online-only materials Duplicate author/reviewer accounts in Manuscript Central: Please do not create a duplicate author account when entering authors for a newly-submitted manuscript. If details of an account need to be altered, please contact the Editors Questions and inquiries: Please direct all questions and inquiries to the Editors   Post-Submission Information Submission-Related Emails and Online Status The Manuscript Central system sends emails only to the corresponding author (except for copyright release emails for accepted articles). Submitted manuscripts will show in the Manuscript Central Author Center of only the corresponding author. Manuscript Decisions Manuscripts may receive decisions of Reject, Major Revision, Minor Revision, Accept with Edits, or Accept. A manuscript decision of Major Revision or Minor Revision does not guarantee the manuscript will ultimately be accepted. Article type word limits apply to revisions as well as initial submissions. A manuscript with a decision of Accept with Edits will not receive a formal Accept decision until all requested edits are satisfactorily completed. Post-Acceptance Information Permissions Authors are responsible for procuring permissions to reproduce illustrations or tables taken from other publications and must be acknowledged by a complete credit line in the figure legend. The original publisher’s letter of permission should be available for submission to Journal of Adolescent and Young Adult Oncology if requested by the Editors or the Publisher. A full citation should also be included in the Reference section. Page Proofs An email containing a link to the PDF file of the page proof is sent to the corresponding author. The proof should be read carefully and returned within 3 business days to the Publisher with the author’s/authors’ approval or corrections. Reprints Reprints may be ordered by following the special instructions that accompany page proofs and should be ordered at the time the corresponding author returns the corrected page proofs. Reprints ordered after an issue is printed will be charged at a substantially higher rate. Publisher Journal of Adolescent and Young Adult Oncology is published quarterly by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215, Tel: (914) 740-2100; Fax: (914) 740-2101; Email: info@liebertpub.com;  Website: www.liebertpub.com/JAYAO Editorial Board Editor-in-Chief Leonard S. Sender, MD University of California, Irvine     and CHOC Children’s Hospital Orange, CA kcloudhansen@liebertpub.com  Managing Editor  Karen Cloud-Hansen, PhD kcloudhansen@liebertpub.com Associate Editors Karen H. Albritton, MD Cook Children's Medical Center and University of North Texas Health Science Center Fort Worth, TX Ronald D. Barr, MB ChB, MD McMaster University Hamilton, Ontario, Canada Brandon Hayes-Lattin, MD OHSU Knight Cancer Institute Portland, OR Owen P. Smith, MA, MB Trinity College Dublin, Ireland David M. Thomas, MBBS, PhD The Garvan Institute of Medical Research Darlinghurst, Australia  Section Editors Breast Cancer    Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute Boston, MA Gastrointestinal Oncology  Jason A. Zell, DO, MPH University of California, Irvine Orange, CA Gynecologic Oncology   Bradley J. Monk, MD Creighton University School of Medicine at St. Joseph’s Hospital   and Medical Center Phoenix, AZ Head & Neck Cancer  Louise Davies, MD, MS Dartmouth College Hanover, NH Leukemia & Lymphoma  Josep-Maria Ribera, MD, PhD ICO-Hospital Germans Trias i Pujol Badalona, Barcelona, Spain Melanoma  Vernon K. Sondak, MD H. Lee Moffitt Cancer Center & Research Institute Tampa, FL Neuro-Oncology Timothy Cloughesy, MD University of California, Los Angeles Los Angeles, CA Oncofertility  Teresa K. Woodruff, PhD Northwestern University Chicago, IL Psychosocial Issues  Brad Zebrack, PhD, MSW, MPH University of Michigan Ann Arbor, MI Radiation Oncology   Daniel J. Indelicato, MD University of Florida Jacksonville, FL Sarcoma  Stefan S. Bielack, MD Klinikum Stuttgart - Olgahospital Stuttgart, Baden-Württemberg, Germany Survivorship Patricia A. Ganz, MD University of California, Los Angeles Los Angeles, CA Testicular Cancer  Craig R. Nichols, MD Virginia Mason Medical Center Seattle, WA Editorial Board Peter C. Adamson, MD Children’s Oncology Group Children’s Hospital of Philadelphia Philadelphia, PA Sylvie Aubin, PhD McGill University Montréal, Québec, Canada Laurence H. Baker, DO University of Michigan Ann Arbor, MI Charles D. Blanke, MD SWOG OHSU Knight Cancer Institute Portland, OR Archie Bleyer, MD St. Charles Health System Bend, OR Wendy R. Brewster, MD, PhD University of North Carolina, Chapel Hill Chapel Hill, NC Mitchell  S. Cairo, MD New York Medical College Valhalla, NY Louis S. Constine, MD University of Rochester Rochester, NY Simon Davies Teen Cancer America Los Angeles, CA  Philip J. Di Saia, MD Gynecologic Oncology Group University of California, Irvine Orange, CA Michael G. Douvas, MD University of Virginia  Charlottesville, VA Andrea Ferrari, MD Istituto Nazionale Tumori Milan, Italy Anna R.K. Franklin, MD University of Texas MD Anderson Cancer Center Houston, TX Helen Gogas, MD University of Athens Athens, Greece Pamela  S. Hinds, PhD, RN Children’s National Medical Center Washington, DC Barbara L. Jones, PhD, MSW University of Texas at Austin Austin, TX Laxmi A. Kondapalli, MD, MSCE University of Colorado Anschutz Medical Campus Aurora, CO Bryan M. Langholz, PhD University of Southern California Los Angeles, CA Michael P. Link, MD Stanford University  Palo Alto, CA Ralph A. Manchester, MD University of Rochester Rochester, NY Yousif  Matloub, MD Rainbow Babies & Children's Hospital and Case Western Reserve University Cleveland, OH Charles G. Mullighan, MBBS, MSc, MD St. Jude Children's Research Hospital Memphis, TN Antonio Sergio Petrilli, MD, PhD Federal University of São Paulo São Paulo, Brazil Brad H. Pollock, MPH, PhD University of Texas Health Science Center at San Antonio San Antonio, TX Ching-Hon Pui, MD St. Jude Children's Research Hospital Memphis, TN Amelie G. Ramirez, DrPH University of Texas Health Science Center at San Antonio San Antonio, TX  Gregory H. Reaman, MD U.S. Food and Drug Administration Children’s National Medical Center Washington, DC Leslie L. Robison, PhD St. Jude Children's Research Hospital Memphis, TN Kathleen  S. Ruccione, MPH, RN Children’s Hospital Los Angeles Los Angeles, CA Nita L. Seibel, MD National Cancer Institute Bethesda, MD Peter H. Shaw, MD Children’s Hospital of Pittsburgh Pittsburgh, PA Ashley Wilder Smith, PhD, MPH National Cancer Institute Bethesda, MD Nao Suzuki, MD, PhD St. Marianna University School of Medicine Kanagawa, Japan Eduardo Vilar, MD, PhD University of Texas MD Anderson Cancer Center Houston, TX Elizabeth A. Williams, PhD Tennessee State University Nashville, TN Cheryl L. Willman, MD University of New Mexico Albuquerque, NM  Leonard A. Zwelling, MD, MBA Zwelling Consultants LLC Bellaire, TX